Globeimmune, Inc. (OTCMKTS:GBIM – Get Free Report)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.00 and traded as high as $0.00. Globeimmune shares last traded at $0.00, with a volume of 0 shares trading hands.
Globeimmune Trading Down 100.0%
About Globeimmune
GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
Featured Articles
- Five stocks we like better than Globeimmune
- 3 Tickers Leading a Meme Stock Revival
- Rayonier-PotlatchDeltic Merger Signals Industry Upside
- How to Invest in Biotech Stocks
- Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
- Profitably Trade Stocks at 52-Week Highs
- This Defense Stock Has a $57B Backlog and New AI Tailwinds
Receive News & Ratings for Globeimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globeimmune and related companies with MarketBeat.com's FREE daily email newsletter.
